ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 752

Role of the Six-Minute Walk Test in Systemic Sclerosis: Five Years Evolution

Els Vandecasteele1, Karin Melsens2, Filip De Keyser3, Michel De Pauw4, Ellen Deschepper5, Saskia Decuman6, Yves Piette2, Kristof Thevissen7, Guy Brusselle8 and Vanessa Smith3, 1Dep of Cardiology, University Hospital Ghent, Ghent, Belgium, 2Ghent University Hospital, Department of Rheumatology, Ghent, Belgium, Ghent, Belgium, 3Ghent University, Department of Internal Medicine, Ghent, Belgium, Ghent, Belgium, 4Dep of cardiology, University Hospital Ghent, Ghent, Belgium, 5Biostatistics Unit, UGent, Ghent, Belgium, 6Department of Internal Medicine, Ghent University, Ghent, Belgium, 7University Hospital Ghent, Ghent, Belgium, 8Gent University, Gent, Belgium

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: exercise, interstitial lung disease and systemic sclerosis, Pulmonary Involvement

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 5, 2017

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Clinical Aspects and Therapeutics Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Title

Role of the Six-Minute Walk Test in Systemic Sclerosis: five years evolution.

Background/Purpose: Interstitial lung disease (ILD) and pulmonary arterial hypertension (PAH) are the leading causes of death in Systemic Sclerosis (SSc) patients. Although the six-minute walk test (6MWT) is used for evaluating ILD and PAH in clinical practice, no data are available on the natural evolution of the six-minute walk distance (6MWD) in SSc patients without ILD and PAH.

Methods: Prospectively collected data of the first 6MWT (at baseline or at 6-month follow-up) and the 6MWTs at 18-, 30-, 42-, 54-, and 66-month visit of 165 consecutive SSc patients without ILD and PAH, included in the Ghent University Systemic Sclerosis Cohort between May 2006 and December 2016 were analysed.

Results: The mean 6MWD during the baseline 6MWT of 165 SSc patients without ILD and PAH (35% limited SSc, 56% limited cutaneous SSc, 9% diffuse cutaneous SSc) was 484.20+/-92.65m with no significant difference in the distance walked at different follow-up visits as compared to baseline. 96-100% of the SSc patients without ILD and PAH performed a 6MWT during the different follow-up visits.

Conclusion: In SSc without ILD and PAH, the 6MWT is feasible and the 6MWD is clinically stable over a 66 months period.  A 6MWT performed at the time of SSc diagnosis may be used as a reference 6MWD for those SSc patients who develop ILD or PAH during follow-up.


 

Table 1. Baseline characteristics of 165 SSc without ILD and PAH.

Characteristic

N

 

Age (years) °

165

48.02+/-13.19

♀/♂ *

165

124/41 (75.2/24.8)

Raynaud *

165

162 (98.2)

Disease duration since first Raynaud (months)#

162

60 (20-176)

Disease duration since first non-Raynaud (months)#

137

26 (10-74)

LSSc/LcSSc/DcSSc *

165

58/92/15

(35.2/55.8/9.1)

mRSS #

165

3 (0-7)

DAS #

162

0.5 (0-1.5)

HAQ #

141

0.25 (0.00-0.63)

AntiScl70 AB *

165

16 (9.7)

ACA *

165

100 (60.6)

FVC (%pred) #

165

113 (99-126)

DLCO (%pred) #

165

77 (69-88)

Peak TVR (m/s) #

131

2.3 (2.1-2.4)

6MWD (m) °

165

484.20+/-92.65

°: mean+/-SD, *: n (%), #: median (IQR), mRSS: modified Rodnan Skin Score, DAS: disease activity score, HAQ: health assessment questionnaire, AntiScl70 AB: anti-topoisomerase I antibodies, ACA: anti-centromere antibodies, FVC: forced vital capacity, expressed as % of the predicted value, DLCO: diffusing capacity of the lung for carbon monoxide, expressed as % of the predicted value, Peak TVR: peak tricuspid valve regurgitation velocity, m/s: meter per second, 6MWD: six-minute walk distance.

Table 2. Evolution of the 6MWD from baseline to the different follow-up visits

 

N 6MWT

N Tx visit

6MWD T0 (m)

mean+/-SD

6MWD Tx(m)

mean+/-SD

Pearson’s correlation coefficient

Mean Difference (95%CI) (m)

P

T0 vs T18

130

130

487.13+/-94.41

487.95+/-96.30

0.817

0.82 (-9.19; 10.83)

0.871

T0 vs T30

98

101

490.62+/-90.31

488.07+/-85.98

0.745

-2.55 (-15.20; 10.10)

0.690

T0 vs T42

77

80

481.56+/-95.56

466.52+/-105.49

0.694

-15.04 (-33.01; 2.93)

0.100

T0 vs T54

65

68

480.79+/-97.47

480.86+/-102.53

0.765

0.08 (-16.96; 17.12)

0.993

T0 vsT66

46

46

480.37+/-90.25

483.74+/-95.85

0.564

3.37 (-22.49; 29.23)

0.794

N 6MWT: number of patients performing a six-minute walk test, N Tx visit: number of patients having a follow-up visit at month x, 6MWD: six-minute walk distance, T0: baseline visit, Tx: x-month visit, m: meter, SD: standard deviation, CI: confidence interval


Disclosure: E. Vandecasteele, None; K. Melsens, None; F. De Keyser, None; M. De Pauw, None; E. Deschepper, None; S. Decuman, None; Y. Piette, None; K. Thevissen, None; G. Brusselle, None; V. Smith, Fund for Scientific Research Flanders, 2.

To cite this abstract in AMA style:

Vandecasteele E, Melsens K, De Keyser F, De Pauw M, Deschepper E, Decuman S, Piette Y, Thevissen K, Brusselle G, Smith V. Role of the Six-Minute Walk Test in Systemic Sclerosis: Five Years Evolution [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/role-of-the-six-minute-walk-test-in-systemic-sclerosis-five-years-evolution/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/role-of-the-six-minute-walk-test-in-systemic-sclerosis-five-years-evolution/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology